Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 8,642,012

« Back to Dashboard

Which drugs does patent 8,642,012 protect, and when does it expire?

Patent 8,642,012 protects RAVICTI and is included in one NDA. There has been one Paragraph IV challenge on Ravicti.

This patent has nineteen patent family members in eleven countries.

Summary for Patent: 8,642,012

Title:Methods of treatment using ammonia-scavenging drugs
Abstract: The invention provides a method for determining a dose and schedule and making dose adjustments of PBA prodrugs used to treat nitrogen retention states, or ammonia accumulation disorders, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The invention provides methods to select an appropriate dosage of a PBA prodrug based on the patient's dietary protein intake, or based on previous treatments administered to the patient. The methods are applicable to selecting or modifying a dosing regimen for a subject receiving an orally administered ammonia scavenging drug.
Inventor(s): Scharschmidt; Bruce (South San Francisco, CA)
Assignee: Hyperion Therapeutics, Inc. (South San Francisco, CA)
Application Number:12/350,111
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Horizon Theraps Inc
RAVICTI
glycerol phenylbutyrate
LIQUID;ORAL203284-001Feb 1, 2013RXYesYes8,642,012► Subscribe DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,642,012

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2735218► Subscribe
Canada2735234► Subscribe
Denmark2330892► Subscribe
European Patent Office2330892► Subscribe300854Netherlands► Subscribe
European Patent Office2330892► SubscribeCA 2016 00062Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc